MediGene AG divests Oncolytic Herpes Simplex Viruses (oHSV) program to Catherex, Inc.
MediGene to receive a 40% stake in Catherex
13-Apr-2010 -
MediGene AG announced that MediGene, Inc., its wholly owned subsidiary, has assigned its development program of oncolytic herpes simplex viruses (oHSV), to Catherex, Inc., a private US company located in Philadelphia, Pennsylvania. In return, MediGene receives a 40% stake in Catherex, making ...
clinical trials
glioma
herpes simplex
+2